Nicholas Petrick

Nicholas Petrick

Auto-generated profile, based on publicly available information

Nicholas Petrick

U.S. Food and Drug Administration

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2018 in Journal of Medical Imaging
Verified
Journal Article
Closed access
PDF file
SASamuel G. Armato
Samuel G. Armato
HHHenkjan J. Huisman
Henkjan J. Huisman
Karen DrukkerKaren Drukker
Karen Drukker
LHLubomir Hadjiiski
Lubomir Hadjiiski
JKJustin S. Kirby
Justin S. Kirby
KFKeyvan Farahani
Keyvan Farahani
Grand challenges stimulate advances within the medical imaging research community; within a competitive yet friendly environment, they allow for a direct comparison of algorithms through a well-defined, centralized infrastructure. The tasks of the two-part PROSTATEx Challenges (the PROSTATEx Challenge and the PROSTATEx-2 Challenge) are (1) the computerized classification of clinically significant prostate lesions and (2) the computerized determination of Gleason Grade Group in prostate cancer, both based on multiparametric magnetic resonance images. The challenges incorporate well-vetted cases for training and testing, a centralized performance assessment process to evaluate results, and an established infrastructure for case dissemination, communication, and result submission. In the PROSTATEx Challenge, 32 groups apply their computerized methods (71 methods total) to 208 prostate lesions in the test set. The area under the receiver operating characteristic curve for these methods in the task of differentiating between lesions that are and are not clinically significant ranged from 0.45 to 0.87; statistically significant differences in performance among the top-performing methods, however, are not observed. In the PROSTATEx-2 Challenge, 21 groups apply their computerized methods (43 methods total) to 70 prostate lesions in the test set. When compared with the reference standard, the quadratic-weighted kappa values for these methods in the task of assigning a five-point Gleason Grade Group to each lesion range from −0.24 to 0.27; superiority to random guessing can be established for only two methods. When approached with a sense of commitment and scientific rigor, challenges foster interest in the designated task and encourage innovation in the field.

9 November 2018 in IEEE Journal of Biomedical and Health Informatics
Verified
Journal Article
Closed access
APAria Pezeshk
Aria Pezeshk
SHSardar Hamidian
Sardar Hamidian
NPNicholas Petrick
Nicholas Petrick
BSBerkman Sahiner
Berkman Sahiner
Deep 2D convolutional neural networks (CNNs) have been remarkably successful in producing record-breaking results in a variety of computer vision tasks. It is possible to extend CNNs to three dimensions using 3D kernels to make them suitable for volumetric medical imaging data such as CT or MRI, but this increases the processing time as well as the required number of training samples (due to the higher number of parameters that need to be learned). In this work, we address both of these issues for a 3D CNN implementation through the development of a two-stage computer-aided detection system for automatic detection of pulmonary nodules. The first stage consists of a 3D fully convolutional network (FCN) for fast screening and generation of candidate suspicious regions. The second stage consists of an ensemble of 3D CNNs trained using extensive transformations applied to both the positive and negative patches to augment the training set. To enable the second stage classifiers to learn differently, they are trained on false positive patches obtained from the screening model using different thresholds on their associated scores as well as different augmentation types. The networks in the second stage are averaged together to produce the final classification score for each candidate patch. Using this procedure, our overall nodule detection system called DeepMed is fast and can achieve 91% sensitivity at 2 false positives per scan on cases from the LIDC dataset.

26 January 2024 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
ASAubrey A. Shick
Aubrey A. Shick
CWChristina M. Webber
Christina M. Webber
NKNooshin Kiarashi
Nooshin Kiarashi
JWJessica P. Weinberg
Jessica P. Weinberg
ADAneesh Deoras
Aneesh Deoras
MDMatthew C. Diamond
Matthew C. Diamond

1 July 2002 in Radiology
Verified
Journal Article
Closed access
NPNicholas Petrick
Nicholas Petrick
BSBerkman Sahiner
Berkman Sahiner
HCHeang-Ping Chan
Heang-Ping Chan
MHMark A. Helvie
Mark A. Helvie
SPSophie Paquerault
Sophie Paquerault
Lubomir HadjiyskiLubomir Hadjiyski
Lubomir Hadjiyski
To evaluate the performance of a computer-aided diagnosis (CAD) mass-detection algorithm in marking preoperative masses. Digitized mammograms were processed with an adaptive enhancement filter followed by a local border refinement stage. Features were then extracted from each detected structure and used to identify potential masses. The performance of the algorithm was evaluated in independent cases obtained from 263 patients from two institutions. Each case contained one or more pathologically proved breast masses. Contralateral mammograms obtained in the same patients that did not contain a visible lesion were used to estimate the CAD marker rate for the algorithm. The tradeoff between detection sensitivity and the number of CAD marks was analyzed in this study. Malignant masses were detected with the computer in 87% (135 of 156), 83% (130 of 156), and 77% (120 of 156) of the malignant cases at CAD marker rates of 1.5, 1.0, and 0.5 marks per mammogram, respectively. The difference between malignant mass-detection performance in subsets of cases collected at each institution was found to be less than 1%. The detection accuracy for benign masses was lower than that for malignant masses. This mass-detection algorithm had a high sensitivity for detection of malignant masses. It may be useful as a second opinion in mammographic interpretation.

14 December 2016 in IEEE Transactions on Medical Imaging
Verified
Journal Article
Closed access
APAria Pezeshk
Aria Pezeshk
NPNicholas Petrick
Nicholas Petrick
WCWeijie Chen
Weijie Chen
BSBerkman Sahiner
Berkman Sahiner
The performance of a classifier is largely dependent on the size and representativeness of data used for its training. In circumstances where accumulation and/or labeling of training samples is difficult or expensive, such as medical applications, data augmentation can potentially be used to alleviate the limitations of small datasets. We have previously developed an image blending tool that allows users to modify or supplement an existing CT or mammography dataset by seamlessly inserting a lesion extracted from a source image into a target image. This tool also provides the option to apply various types of transformations to different properties of the lesion prior to its insertion into a new location. In this study, we used this tool to create synthetic samples that appear realistic in chest CT. We then augmented different size training sets with these artificial samples, and investigated the effect of the augmentation on training various classifiers for the detection of lung nodules. Our results indicate that the proposed lesion insertion method can improve classifier performance for small training datasets, and thereby help reduce the need to acquire and label actual patient data.

23 June 2023 in Journal of Medical Imaging
Verified
Journal Article
Open access
PDF file
NPNicholas Petrick
Nicholas Petrick
WCWeijie Chen
Weijie Chen
JDJana Delfino
Jana Delfino
BGBrandon D. Gallas
Brandon D. Gallas
YKYanna Kang
Yanna Kang
RSRavi K. Samala
Ravi K. Samala
Devices incorporating artificial intelligence and machine learning (AI/ML) can be found in many areas of medicine, and the U.S. Food and Drug Administration (FDA) and Center for Devices and Radiological Health (CDRH) have a history regulating medical AI/ML technologies.1 As an example, a semi-automated cervical cytology slide reader incorporating neural network processors was first approved by the FDA in 1995.2 FDA receives a high volume of premarket submission inquiries for products leveraging AI/ML technologies, and we expect this trend to continue going forward. Q-submissions are a mechanism for device developers to ask questions and obtain official FDA feedback prior to a formal premarket submission.3 Q-submissions are highly recommended to help address a question prior to a full device submission.